肠道微生物群的组成和与酒精有关的肝病:系统性审查和元分析
Xuanxuan Niu1, Lei Ma1, Zhewen Zhou1
1Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, 8 Jingshundong Street, Chaoyang District, Beijing 100015, China.
Drug and alcohol dependence
|December 3, 2025
概括
与酒精有关的肝病 (ARLD) 与显著的肠道微生物组变化有关. 一项元分析显示,ARLD患者的微生物多样性减少,并转向促炎细菌,这表明肠道微生物群是治疗点.
科学领域:
- 胃肠病学和肝病学
- 微生物学 微生物学
- 基因组学就是基因组学.
背景情况:
- 肠道微生物组在与酒精有关的肝病 (ARLD) 的发展和进展中起着至关重要的作用.
- 了解ARLD的肠道微生物组变化对于开发有效的治疗策略至关重要.
研究的目的:
- 系统地审查和元分析与ARLD相关的肠道微生物组的变化.
- 在ARLD患者中提供肠道微生物多样性和丰度变化的全面概述.
主要方法:
- 在PubMed,Embase和Web of Science数据库中进行系统搜索 (2015年1月 - 2024年9月).
- 包括报告肠道微生物群分析,ARLD中的多样性和丰度的研究.
- 两个阶段的选和两个审查员的独立数据提取.
主要成果:
- 与对照组相比,ARLD患者的α-多样性指数 (Shannon,Chao1,OTUs) 显著下降.
- 在大多数研究中报告了β-多样性的显著差异 (在21个中16个).
- 在ARLD中观察到的抗炎微生物的减少和促炎微生物的丰富.
结论:
- ARLD的特点是肠道微生物多样性下降.
- 减少有益的抗炎微生物和增加促炎微生物是ARLD的关键特征.
- 肠道微生物组是ARLD管理的有希望的治疗点.
相关概念视频
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
196
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
196


